In 2017, deal volume in the biopharma space slowed for the third consecutive year. Value in all of the pharma and life sciences sector totaled only about $181 billion, down 23% from a year earlier, according to PricewaterhouseCoopers.

But according to Intec Pharma Ltd. (NTEC) Chief Executive Officer and Vice Chairman Jeffrey Meckler, a slowdown one year doesn't necessarily portend a slowdown the next year. Rather, innovation is often what drives mergers and acquisitions in biopharma.

"Where there's real innovation, there's always someone willing to pay for it," Meckler said.

More from Mergers and Acquisitions

Jim Cramer on Broadcom-CA: This Is the Antithesis of a Semiconductor Deal

Jim Cramer on Broadcom-CA: This Is the Antithesis of a Semiconductor Deal

Boeing Stock Soars on New Zealand Deal, Saudi Arabian Airlines Report

Boeing Stock Soars on New Zealand Deal, Saudi Arabian Airlines Report

Boeing to Take Control of Embraer's $4.75 Billion Commercial Business

Boeing to Take Control of Embraer's $4.75 Billion Commercial Business

Walgreens Price Target Is Slashed After Amazon's PillPack Acquisition

Walgreens Price Target Is Slashed After Amazon's PillPack Acquisition

10 Biggest Food Acquisitions of All-Time

10 Biggest Food Acquisitions of All-Time